Therapure Biologics focuses on the development of a portfolio of its own plasma-derived pharmaceutical products using its proprietary technology, PlasmaCap EBA™ and building on Therapure’s biomanufacturing capabilities and plasma protein expertise. Therapure Biologics is able to provide improved efficiencies and unprecedented precision in the extraction of plasma proteins.

Our initial focus is on three important plasma proteins: intravenous immunoglobulin (IVIG), albumin, and alpha-1 antitrypsin (AAT) which are established products in the plasma protein industry with growing demand. Using our extensive knowledge in plasma proteins and working with key industry players, we have developed a program to launch these products to address the needs of the market.

Learn more about our pipeline of plasma proteins.